Literature DB >> 7951865

Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C.

K Moriya1, K Yasuda, K Koike, Y Ichinose, H Yotsuyanagi, K Kurokawa, S Iino.   

Abstract

A 48-year-old woman developed interstitial pneumonitis while receiving interferon treatment for chronic hepatitis C. Laboratory studies prior to treatment showed elevated serum alanine aminotransferase levels, but chest X-rays and physical examination revealed no abnormalities suggestive of interstitial pneumonitis. At the 9th week of interferon treatment (total dose, 380 MU of recombinant interferon-alpha, without other medications), the patient began to complain of cough and exertional dyspnea. A chest X-ray film revealed diffuse reticulo-nodular shadows in bilateral lung fields, suggesting a diagnosis of interstitial pneumonitis. A marked increase in lymphocyte count was observed in bronchoalveolar lavage fluid and a diagnosis of interstitial pneumonitis was made as a result of transbronchial lung biopsy. Her clinical symptoms and abnormal lung shadows were reversible, improving within a month of the discontinuation of interferon, and disappearing promptly after exogenous corticosteroid was instituted. This may be the first case of drug-induced interstitial pneumonitis occurring during the course of treatment with interferon alone. We should be aware of the possibility of interstitial pneumonitis developing during treatment of chronic hepatitis C with interferon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7951865     DOI: 10.1007/BF02361253

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

Review 2.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts).

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

3.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

6.  Interferon therapy for non-A, non-B chronic hepatitis.

Authors:  S Iino; K Hino; T Kondo; K Koike; K Yasuda; H Yotsuyanagi; K Kurokawa
Journal:  Gastroenterol Jpn       Date:  1991-07

Review 7.  Drug-induced pulmonary disease. Part 1: Cytotoxic drugs.

Authors:  J A Cooper; D A White; R A Matthay
Journal:  Am Rev Respir Dis       Date:  1986-02

8.  Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus.

Authors:  T Ueda; K Ohta; N Suzuki; M Yamaguchi; K Hirai; T Horiuchi; J Watanabe; T Miyamoto; K Ito
Journal:  Am Rev Respir Dis       Date:  1992-07

9.  Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma.

Authors:  R J Shaw; S H Benedict; R A Clark; T E King
Journal:  Am Rev Respir Dis       Date:  1991-01

10.  Non-A, non-B chronic hepatitis is chronic hepatitis C: a sensitive assay for detection of hepatitis C virus RNA in the liver.

Authors:  K Hosoda; M Omata; O Yokosuka; N Kato; M Ohto
Journal:  Hepatology       Date:  1992-05       Impact factor: 17.425

View more
  5 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha.

Authors:  S Yamaguchi; K Kubo; K Fujimoto; T Honda; M Sekiguchi; T Sodeyama
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

Review 3.  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

Authors:  Fan-Pu Ji; Zheng-Xiao Li; Hong Deng; Hong-An Xue; Yuan Liu; Min Li
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

4.  Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].

Authors:  Vanna Chiarion-Sileni; Paola Del Bianco; Antonella Romanini; Michele Guida; Adriano Paccagnella; Maurizio Dalla Palma; Emanuele Naglieri; Ruggero Ridolfi; Barbara Silvestri; Maria Michiara; Gian Luca De Salvo
Journal:  BMC Cancer       Date:  2006-02-27       Impact factor: 4.430

Review 5.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.